Deerfield Partners
4
42M
4
4
- Stages of investment
- Areas of investment
Summary
The company was established in North America in United States. The main office of represented Corporate Investor is situated in the San Francisco.
The usual cause for the fund is to invest in rounds with 8 partakers. Despite the Deerfield Partners, startups are often financed by Oak Investment Partners, L Capital Partners, Johnson & Johnson Development Corporation. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Vivo Capital, Venrock. In the next rounds fund is usually obtained by Skyline Ventures, Silicon Valley Bank, RA Capital Management.
This Deerfield Partners works on 71 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2014. The fund is generally included in less than 2 deals every year.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Bluebird Bio, Tengion, Ocera Therapeutics. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Biopharma, Health Care.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Exits
- 4
- Investments by industry
- Biotechnology (4)
- Health Care (2)
- Pharmaceutical (2)
- Genetics (2)
- Medical (1) Show 3 more
- Investments by region
-
- United States (4)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 20
- Avg. valuation at time of investment
- 10M
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
- Avg. multiplicator
- 0.43
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | 31 Jul 2013 | Biotechnology, Health Care, Genetics, Pharmaceutical | Late Stage Venture | 60M | United States, Massachusetts |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.